|Previous Section||Index||Home Page|
|Total notifiable offences|
Mr. Lansley: To ask the Secretary of State for Health what the cost has been of the development of the Fuel for Living" booklet; how many copies of the booklet will be published; at what cost; and if she will make a statement. 
The Fuel for Living" recipe booklet is part of the 5 A DAY campaign, which provides information and practical advice to improve the diet. The booklet targets the young independent group of 16 to 24-year-olds, who have a lower than average intake of fruit and vegetables so there is a need to provide information and help to improve their diet.
13 Feb 2006 : Column 1750W
Mr. Meacher: To ask the Secretary of State for Health in respect of the proposed NHS reforms outlined in Health Reform in England; update and next steps", whether practice based contracting will apply to all care or only to non-hospital care. 
Tim Loughton: To ask the Secretary of State for Health (1) if she will list the attention deficit hyperactivity disorder support groups which receive funding from the NHS; and how much each has received in 200506; 
Mr. Byrne: Information about national health service support for attention deficit hyperactivity disorder support groups is not collected centrally. However, the Department currently supports one attention deficit hyperactivity disorder support group via the section 64 grant scheme. In 200506, the National Attention Deficit Disorder Information and Support Service are receiving £40,000 as a contribution towards their central administrative costs.
Mr. Lansley: To ask the Secretary of State for Health how many patient reports of adverse drug reactions have been received (a) online and (b) through a yellow card form in each month since patients were permitted to report adverse drug reactions directly. 
Jane Kennedy: Reports of suspected adverse drug reaction (ADR) reports are collected by the Medicines and Healthcare products Regulatory Agency (MHRA) and Commission for Human Medicines (CHM) through the spontaneous reporting scheme, the yellow card scheme.
Following recommendations from an independent review of access to the yellow card scheme, patients and their representatives are now encouraged to report suspected adverse drug reactions directly to the MHRA and CHM. Direct reporting from patients was launched as a small-scale pilot in January 2005 and expanded to a United Kingdom-wide pilot in October 2005. Patients are able to submit reports both electronically and via a purpose designed paper yellow card.
The table shows the total number of patient adverse drug reaction (ADR) reports received each month between 17 January 2005 and 31 December 2005, along with a breakdown of the number of paper and electronic internet reports.
13 Feb 2006 : Column 1751W
It is important to note that the submission of a suspected ADR report does not necessarily mean that it was caused by the drug. Many factors have to be taken into account in assessing causal relationships, including temporal association, the possible contribution of concomitant medication and the underlying disease.
Mr. Jenkins: To ask the Secretary of State for Health what assessment her Department has made of the effects of drinking alcohol (a) socially and (b) alone; and what assessment she has made of the different effects of drinking particular alcoholic drinks. 
Kelvin Hopkins: To ask the Secretary of State for Health what her Department estimates to be the prevalence service utilisation ratio for alcohol-dependent individuals accessing treatment in (a) England and (b) each region. 
Caroline Flint [holding answer 24 January 2006]: The Government's alcohol needs assessment research project (ANARP) research, published in November 2005, estimates the gap between those alcohol-dependent individuals seeking treatment and the level of treatment services that is available.
|Prevalence service utilisation in need of treatment/in treatment|
|All (Average) Regions||18.0|
|Yorkshire and Humber||46.0|
Jane Kennedy: Alimta is licensed for the treatment of malignant pleural mesothelioma and can be prescribed across the national health Service for those patients who fit the licensed criteria with the agreement of the clinicians and primary care trusts (PCTs) concerned.
Funding for licensed treatments should not be withheld because guidance from NICE is unavailable. In these circumstances, we expect PCTs to take full account of available evidence when reaching funding decisions. This is confirmed in Health Service Circular 1999/176", which asks NHS bodies to continue with local arrangements for the managed introduction of new technologies where guidance from NICE is not available at the time the treatment or technology first became available.
|Next Section||Index||Home Page|